peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
22 February – More than 60 MPs have signed a House of Commons motion calling for the resignation of Speaker Sir Lindsay Hoyle. The Independent Parliamentary Standards Authority launches an investigation into allegations that Pensions Minister Paul Maynard used public funds to finance his campaign. The UK government announces that legislation will be introduced to clear hundreds of sub-postmasters in England and Wales who were wrongly convicted as a result of the Horizon IT scandal. Argyll and Bute Council votes to raise its council tax by 10%, and rejects the Scottish Government's council tax freeze by doing so. Former prime minister Liz Truss addresses the Conservative Political Action Conference in the United States, where she said Western civilisation is at risk if Conservatives do not develop a louder voice, and attributes the downfall of her administration to "antagonism" from the establishment. She subsequently appears on a podcast with former Trump strategist Steve Bannon, where she remains silent as Bannon describes the far-right political activist Tommy Robinson as a "hero". 23 February – A UK government commissioned report prepared by Lord Walney recommends giving police extra powers to tackle protests outside Parliament in order to protect politicians against "intimidation" that could influence the way they vote. Sammy Wilson announces his resignation as DUP Chief Whip at Westminster. The UK agrees a deal with the European Border and Coast Guard Agency (Frontex) to work more closely to prevent migrants crossing the English Channel in small boats.
Moving forward, you'll see the DC movie universe being a universe, but one that comes from the heart of the filmmaker who's creating them." Additionally, DC began focusing on films "completely separate from everything else, set entirely outside" the DCEU as part of a new label, with the first film centered on the Joker. Following the commercial failure of Justice League (2017), which ended the DCEU approach spearheaded by Snyder, Warner Bros. executives reportedly reached out to Feige to have him lead the development of DC films but the talks "fizzled". In August 2022, Warner Bros. Discovery CEO David Zaslav announced a 10-year plan for the DC Extended Universe similar to the one that Horn and Iger employed with Feige for the MCU, with James Gunn and Peter Safran appointed in October 2022 to serve as the co-chairmen and co-CEOs of the newly formed DC Studios to develop a new shared universe, the DC Universe, the first content for which was announced in January 2023. By July 2024, both Feige and Gunn had expressed interest in one day creating a crossover between the two franchises, though both noted it was not something actively being discussed or considered. Gunn revealed following the second-season finale of Peacemaker in October 2025, that he had wanted to show Wade Wilson / Deadpool behind one of the alternate universe doors in the Quantum Unfolding Chamber and had reached out to Deadpool actor Ryan Reynolds about it, who was interested in appearing.
== Oxygen-16 == Oxygen-16 (symbol: 16O or 168O) is a stable isotope of oxygen, with 8 neutrons and 8 protons in its nucleus, making it a doubly magic nuclide. It is the most abundant isotope of oxygen, accounting for about 99.76% of all oxygen. The relative and absolute abundances of oxygen-16 are high because it is a principal product of stellar evolution. It can be made by stars that were initially made exclusively of hydrogen. Most oxygen-16 is synthesized at the end of the helium fusion process in stars. The triple-alpha process creates carbon-12, which captures an additional helium-4 to make oxygen-16. It is also created by the neon-burning process. Prior to the definition of the dalton based on 12C, one atomic mass unit was defined as one sixteenth of the mass of an oxygen-16 atom. Since physicists referred to 16O only, while chemists meant the natural mix of isotopes, this led to slightly different mass scales.
=== Hydrogen breath test === In a hydrogen breath test, the most accurate lactose intolerance test, after an overnight fast, 25 grams of lactose (in a solution with water) are swallowed. If the lactose cannot be digested, enteric bacteria metabolize it and produce hydrogen, which, along with methane, if produced, can be detected on the patient's breath by a clinical gas chromatograph or compact solid-state detector. The test takes about 2.5 hours to complete. If the hydrogen levels in the patient's breath are high, they may have lactose intolerance. This test is not usually done on babies and very young children, because it can cause severe diarrhea.
=== New ownership === In December 2017, Patrick Cryne and his family sold an 80% stake in the club to NewCity Capital's Chien Lee and Pacific Media Group's Paul Conway. They were joined by Indian investor Neerav Parekh and Billy Beane, minority owner of and advisor for the Athletics, who was widely known for the Moneyball film portrayal, as part of an international investor consortium. Barnsley were relegated to the third tier in 2017–18. Following this, the new owners adopted a data-driven approach to identify talents, focusing on young players and team rebuilding. The club appointed Daniel Stendel as head coach, who introduced a high-pressing style of play. Barnsley were promoted back to the Championship the following season. In the 2019–20 season, under new coach Gerhard Struber, Barnsley avoided relegation from the Championship. In 2020–21, under the management of Valérien Ismaël, Barnsley finished fifth place and reached the EFL Championship Play-offs for the first time in 24 years, doing so with the youngest squad and one of the smallest budgets in the division. The Wall Street Journal called Barnsley a "Moneyball experiment". Prior to the 2021–22 season, Markus Schopp was appointed as the new head coach. In November 2021, he was dismissed after seven consecutive defeats. Three weeks later Poya Asbaghi was appointed as his successor. Fortunes improved little as Barnsley were relegated from the 2021–22 EFL Championship following a 2–1 defeat against Huddersfield Town. Asbaghi left the club by mutual consent shortly afterwards.
Sources: en.wikipedia.org
==== Contamination of water supply ==== In 2005, the water supply to the city of Harbin in China with a population of almost nine million people, was cut off because of a major benzene exposure. Benzene leaked into the Songhua River, which supplies drinking water to the city, after an explosion at a China National Petroleum Corporation (CNPC) factory in the city of Jilin on 13 November 2005. When plastic water pipes are subject to high heat, the water may be contaminated with benzene.
== Commercialization == ChromaDex (now Niagen Bioscience) licensed patents for nicotinamide riboside from Dartmouth College, Cornell University, and Washington University in St. Louis in July 2012. The company developed a commercial production process for nicotinamide riboside chloride, trademarking the active ingredient as Niagen. ChromaDex has continued to expand using the brand name Tru Niagen globally while also supplying Niagen as an ingredient to other manufacturers. ChromaDex was in a patent dispute with Elysium Health over the rights to nicotinamide riboside supplements between 2016 and 2023. ChromaDex holds multiple patents related to nicotinamide riboside, including manufacturing methods, compositions, and uses. As of 2023, ChromaDex's patent portfolio for nicotinamide riboside includes 50+ granted patents and numerous pending patent applications worldwide. As of March 19, 2025, ChromaDex was renamed Niagen Bioscience, and now trades under the Ticker Symbol 'NAGE'.
Because a dalton, a unit commonly used to measure atomic mass, is exactly 1/12 of the mass of a carbon-12 atom, this definition of the mole entailed that the mass of one mole of a compound or element in grams was numerically equal to the average mass of one molecule or atom of the substance in daltons, and that the number of daltons in a gram was equal to the number of elementary entities in a mole. Because the mass of a nucleon (i.e. a proton or neutron) is approximately 1 dalton and the nucleons in an atom's nucleus make up the overwhelming majority of its mass, this definition also entailed that the mass of one mole of a substance was roughly equivalent to the number of nucleons in one atom or molecule of that substance. Since the definition of the gram was not mathematically tied to that of the dalton, the number of molecules per mole NA (the Avogadro constant) had to be determined experimentally. The experimental value adopted by CODATA in 2010 is NA = 6.02214129(27)×1023 mol−1. In 2011 the measurement was refined to 6.02214078(18)×1023 mol−1. The mole was made the seventh SI base unit in 1971 by the 14th CGPM.
Cannabis is indigenous to Central or South Asia and its uses for fabric and rope dates back to the Neolithic age in China and Japan. It is unclear when cannabis first became known for its psychoactive properties. The oldest archeological evidence for the burning of cannabis was found in Romanian kurgans dated 3,500 BC, and scholars suggest that the drug was first used in ritual ceremonies by Proto-Indo-European tribes living in the Pontic-Caspian steppe during the Chalcolithic period, a custom they eventually spread throughout Western Eurasia during the Indo-European migrations. Some research suggests that the ancient Indo-Iranian drug soma, mentioned in the Vedas, sometimes contained cannabis. This is based on the discovery of a basin containing cannabis in a shrine of the second millennium BC in Turkmenistan. Cannabis was known to the ancient Assyrians, who discovered its psychoactive properties through the Iranians. Using it in some religious ceremonies, they called it qunubu (meaning "way to produce smoke"), a probable origin of the modern word cannabis. The Iranians also introduced cannabis to the Scythians, Thracians and Dacians, whose shamans (the kapnobatai – "those who walk on smoke/clouds") burned cannabis infructescence to induce trance. The plant was used in China before 2800 BC, and found therapeutic use in India by 1000 BC, where it was used in food and drink, including bhang.
This included works such as Alfred, Lord Tennyson's poem titled The Charge of the Light Brigade, Christina Rossetti's volume of poetry titled Goblin Market and Other Poems, Lewis Carroll's Alice's Adventures in Wonderland, Mary Seacole's autographical account titled Wonderful Adventures of Mrs. Seacole in Many Lands, and Anthony Trollope's novel titled Orley Farm. Samples also argued that vegetarianism in the Victorian era "presented a unique lifestyle choice that avoided meat but promoted an awareness of health", which initially was seen as rebellious but later became more normalized. In Irene Clyde's 1909 feminist utopian novel, Beatrice the Sixteenth, Mary Hatherley accidentally travels through time, discovering a lost world, which is a postgender society named Armeria, with the inhabitants following a strict vegetarian diet, having ceased to slaughter animals for over a thousand years. Some reviewers of the book praised the vegetarianism of the Armerians. James Joyce's 1922 novel, Ulysses is said to have vegetarian themes. Scholar Peter Adkins argued that while Joyce was critical of the vegetarianism of George A.E. Russell, the novel engages with "questions of animal ethics through its portrayal of Ireland's cattle industry, animal slaughter and the cultural currency of meat," unlike some of his other novels.
Sources: en.wikipedia.org
== Society and culture == In the 1970s, John A. Myers, a physician residing in Baltimore, developed a program of injecting vitamins and minerals intravenously for various medical conditions. The formula included 1000 μg of cyanocobalamin. This came to be known as the Myers' cocktail. After he died in 1984, other physicians and naturopaths took up prescribing "intravenous micronutrient therapy" with unsubstantiated health claims for treating fatigue, low energy, stress, anxiety, migraine, depression, immunocompromised, promoting weight loss, and more. However, other than a report on case studies there are no benefits confirmed in the scientific literature. Healthcare practitioners at clinics and spas prescribe versions of these intravenous combination products, but also intramuscular injections of just vitamin B12. A Mayo Clinic review concluded that there is no solid evidence that vitamin B12 injections provide an energy boost or aid weight loss. There is evidence that for elderly people, physicians often repeatedly prescribe and administer cyanocobalamin injections inappropriately, evidenced by the majority of subjects in one large study either having had normal serum concentrations or having not been tested before the injections.
== History == Modafinil was developed in France by neurophysiology professor Michel Jouvet and Lafon Laboratories in the 1970s. Modafinil is the primary metabolite of adrafinil, an earlier compound in the benzhydryl sulfinyl series. Modafinil has been prescribed in France since 1994 under the name Modiodal, and in the United States since 1998 as Provigil. The US Food and Drug Administration approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003. It was approved in the UK in December 2002. In the United States, modafinil is marketed by Cephalon, a biopharmaceutical company acquired by Teva Pharmaceutical Industries in 2011, who acquired the rights from Lafon and purchased the company in 2001. Cephalon introduced armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. Generic versions of modafinil became available in the US in 2012 after extensive patent litigation.
=== 9 May === Fourteen people were killed in RSF shelling on Abu Shouk camp. The Sudanese government ordered the shutdown of the Greater Nile Oil Pipeline carrying petroleum experts by South Sudan, citing RSF attacks.
== CMS/Regulatory == In November 2006, the Centers for Medicare & Medicaid Services (CMS) approved ACHC to accredit suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) as meeting new quality standards under Medicare Part B. In January 2009, the Centers for Medicare & Medicaid Services (CMS) announced the approval of the ACHC for continued Deeming Authority for Home Health Agencies through 2015. Initial approval of Deeming Authority of ACHC for Home Health Agencies was granted in February 2006. On November 27, 2009, ACHC was recognized by the Centers for Medicare & Medicaid Services (CMS) as a national accreditation organization for Hospices that request participation in the Medicare program.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.